Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

The OK Daily Study

27. mai 2026 oppdatert av: Norfolk and Norwich University Hospitals NHS Foundation Trust

Oral Vitamin K2 (Menaquinone-7; MK-7) Supplementation and Effect on Vitamin K Status of Breastfed Term Infants in Early Infancy; a Four-cohort Prospective, Part-randomised, Part-blinded Study.

The OK Daily Study is a multi-centred, part-randomised, part blinded, four cohort study. We are exploring daily dietary supplementation with vitamin K2, specifically menaquinone-7 (MK-7), given to breastfed infants or breastfeeding mothers to see whether this improves the incidence of biochemical vitamin K deficiency in the infants at 2 months postnatal age.

The overall aims are:

  • To compare infant MK-7 supplementation with placebo
  • To compare maternal MK-7 supplementation with placebo
  • To compare infant MK-7 supplementation and maternal MK-7 supplementation
  • To compare infant MK-7 supplementation with vitamin K1 supplementation via infant formula milk.

Once recruited, mother and infant pairs will be grouped initially based on the families' feeding choice. Breastfed infants will then be randomised 2:1 to the infant supplementation or maternal supplementation group. Within the infant supplementation group, infants will either receive MK-7 with vitamin D or a placebo containing vitamin D.

Follow up will occur at 2 months postnatal age (range 2-3 months postnatal age), where bloods and breastmilk samples will be collected to assess the infant and maternal vitamin K status.

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

The OK Daily Study is a multi-centre study taking place in the Norfolk and Norwich University Hospital, Norwich, UK, and Ashford and St Peters' Hospital, Chertsey, UK.

Infants born at ≥37 weeks' gestation will be recruited in the participating site if they meet eligibility criteria and are born within the recruitment window. Recruitment will take place before the mother and infant are discharged from the hospital following birth.

The two main arms of this study are breastfeeding and formula feeding. Mother and infant pairs will initially be allocated based on the family's feeding preferences.

Infants in the breastfeeding arm will be randomised into group 1 or group 2 in a 2:1 ratio. Group 1 allocation will be blinded; group 2 allocation will be open label.

  • Group 1 - infant supplementation group. Infants will receive either 45 micrograms/day of MK-7 with 10 micrograms/day vitamin D3 or a placebo consisting of 10 micrograms/day vitamin D3
  • Group 2 - maternal supplementation group. Mothers in this group will receive 2 mg/day MK-7. All breastfeeding infants in this group will receive 10 micrograms/day of vitamin D3.

Formula fed infants will be in group 3 and will not require any additional supplementation as part of this study. This is because infant formula is already supplemented with adequate amounts of vitamin K1 and vitamin D.

All supplements will be started within 7 days of birth. Vitamin D drops are included for breastfed infants as per national UK guidelines.

Follow up will be as follows:

  • 1 month postnatal visit (range 1-1.5 months) - phone call.

    o Confirmation of eligibility to continue, assessment of compliance with the intervention, and to schedule the in person follow up visit

  • 2 months postnatal (range 2-3 months) - in person visit.

    • All babies will have a single blood sample taken.
    • Mothers who are in group 2 (mothers who have had MK-7 supplementation) and a selection of mothers from group 1 (breastfeeding mothers who are not supplemented with MK-7) will have a single blood sample taken and will be asked to provide a single breastmilk sample
    • Mothers will be asked about their opinions on practising the supplementation.

Blood samples will be analysed for vitamin K status, including Proteins Induced by Vitamin K Absence/antagonism of prothrombin (PIVKA-II) and of osteocalcin (undercarboxylated osteocalcin), dephosphorylated-undercarboxylated matrix gla-protein (dp-ucMGP) and serum vitamin K concentrations (including of vitamin K1 and MK-7). Breastmilk samples will be analysed for vitamin K concentrations (including vitamin K1 and MK-7)

Once this in person follow up visit has been completed, the mother and baby pair will have completed the study.

Studietype

Intervensjonell

Registrering (Antatt)

134

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Barn

Tar imot friske frivillige

Ja

Beskrivelse

Inclusion Criteria:

  • Infants, and mothers of infants, born ≥37 weeks gestational age
  • Standard dose of intramuscular (IM) vitamin K prophylaxis given to the neonate following birth
  • For breastfeeding mothers: the mother intends to exclusively/predominantly breastfeed their baby for at least 2 months

Exclusion Criteria:

  • Inability or refusal to provide informed consent
  • Inability to adhere to or comply with study procedures
  • Babies who meet the inclusion gestation but would otherwise, as part of routine neonatal care, be provided with daily vitamin K drops (i.e. NeoKay drops) at discharge
  • IM vitamin K prophylaxis not received at birth (parents declined vitamin K prophylaxis or parents chose for neonate to receive an oral course of vitamin K prophylaxis instead)
  • Evidence of conjugated hyperbilirubinaemia (these babies are at higher risk of VKDB)
  • Mothers, and babies born to mothers, who are taking any medication that could affect or antagonise vitamin K metabolism (i.e. warfarin, the anti-epileptic drugs phenytoin or carbamazepine, and cephalosporin, rifampicin and isoniazid antimicrobials)

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Annen: Mother and infant pairs who are breastfeeding.

Group 1 = infant supplementation group. Infants in this group will be randomised to receive either 6 drops a day containing 45 micrograms/day of MK-7 plus 10 micrograms/day vitamin D3 OR 10 micrograms/day vitamin D3 only (the active placebo, containing no vitamin K)

Group 2 = maternal supplementation group. Mothers in this group will be given 2 mg/day MK-7 capsules. Infants in this group will receive 10 micrograms/day vitamin D3.
Annen: Combined MK-7 + vitamin D3 drops
6 drops/day providing 45 micrograms/day MK-7 plus 10 micrograms/day of vitamin D3
Andre navn:
  • Vitamin K2 supplemented infant group
Annen: Vitamin D3 Drops
6 drops/day providing 10 micrograms/day vitamin D3 and no supplementary MK-7.
Andre navn:
  • Vitamin K2 unsupplemented group
Annen: MK-7 capsules
1 mg capsules of menaquinone-7, with a daily dose of 2 mg (i.e. 2 capsules per day)
Aktiv komparator: Formula Feeding Infants
Infants who are exclusively formula feeding. These infants will receive the recommended daily amount of vitamin K through their formula milk intake and so will not receive any additional vitamin K supplementation.
Annen: Vitamin D3 Drops
6 drops/day providing 10 micrograms/day vitamin D3 and no supplementary MK-7.
Andre navn:
  • Vitamin K2 unsupplemented group

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Comparison of the proportion of participants who have a PIVKA-II >0.05 AU/mL in the unsupplemented and supplemented infants.
Tidsramme: 2 months postnatal age (range 2-3 months).

PIVKA-II = protein induced by vitamin K antagonism/absence; clotting protein II.

Measured via serum blood sample in arbitrary units/mL. For the primary outcome, this is the comparison between the supplemented and unsupplemented infants.
2 months postnatal age (range 2-3 months).

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Comparison of the proportion of participants who have a PIVKA-II >0.05 AU/mL in the various study groups.
Tidsramme: 2 months postnatal age (range 2-3 months).

PIVKA-II = protein induced by vitamin K antagonism/absence; clotting protein II.

Measured via serum blood sample in arbitrary units/mL. For secondary outcome, this is comparison between remaining groups, other than those assessed in the primary outcome measure.
2 months postnatal age (range 2-3 months).
Comparison of serum levels of osteocalcin (undercarboxylated and carboxylated) between the study groups.
Tidsramme: 2 months postnatal age (range 2-3 months).
Both undercarboxylated and carboxylated levels of osteocalcin will be measured in nanograms/mL.
2 months postnatal age (range 2-3 months).
Comparison of the percentage of undercarboxylated osteocalcin as a proportion of total osteocalcin (%GluOC) between the study groups.
Tidsramme: 2 months postnatal age (range 2-3 months).
Total osteocalcin calculated by the sum of the undercarboxylated and carboxylated osteocalcin values.
2 months postnatal age (range 2-3 months).
Comparison of serum levels of dephosphorylated undercarboxylated matrix Gla Protein in included participants between the study groups.
Tidsramme: 2 months postnatal age (range 2-3 months).
Measured in picomol/mL
2 months postnatal age (range 2-3 months).
Comparison of levels of serum K vitamers (including, but no limited to, vitamin K1 and menaquinone-7) between the study groups.
Tidsramme: 2 months postnatal age (range 2-3 months).
Serum K vitamers will be reported in micrograms/mL.
2 months postnatal age (range 2-3 months).
Comparison of the levels of breastmilk K vitamers (including, but not limited to, vitamin K1 and menaquinone-7) between unsupplemented and supplemented mothers.
Tidsramme: 2 months postnatal age (range 2-3 months).
Serum K vitamers will be reported in nanograms/mL
2 months postnatal age (range 2-3 months).
Investigation of percentage compliance to study supplementation.
Tidsramme: 2 months postnatal age (range 2-3 months).
Amount of remaining supplement will be assessed at follow up. This will then be used to calculate percentage compliance by comparing it to the expected volumes.
2 months postnatal age (range 2-3 months).
Investigation regarding families' opinions about infant and maternal vitamin supplementation.
Tidsramme: 2 months postnatal age (range 2-3 months).
Measured via verbal questioning at follow up.
2 months postnatal age (range 2-3 months).

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Norfolk and Norwich University Hospitals NHS Foundation Trust

Samarbeidspartnere

Guy's and St Thomas' NHS Foundation Trust
University of East Anglia
Maastricht University
Ashford and St. Peter's Hospitals NHS Trust

Etterforskere

  • Hovedetterforsker: Paul Clarke, Professor, Norfolk and Norwich University Hospitals Nhs Foundation Trust

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. august 2026

Primær fullføring (Antatt)

1. september 2027

Studiet fullført (Antatt)

1. august 2028

Datoer for studieregistrering

Først innsendt

13. mai 2026

Først innsendt som oppfylte QC-kriteriene

27. mai 2026

Først lagt ut (Faktiske)

2. juni 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

2. juni 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

27. mai 2026

Sist bekreftet

1. mai 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • 150-12-25

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Kliniske studier på Infant Vitamin K Status

Kliniske studier på Combined MK-7 + vitamin D3 drops

Søk i lignende forsøk

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

CROs by country

CROs in Costa Rica

Forhold

Sjeldne sykdommer

Legemiddelintervensjoner

Kosttilskudd

Sponsor / samarbeidspartnere

Steder

Abonnere